Amitriptyline for Pediatric Migraine: Age and Dosing
Amitriptyline is NOT recommended for children under 12 years of age according to FDA labeling, and even for children 12 and older, the evidence shows it performs no better than placebo for migraine prevention. 1
FDA Age Restrictions
The FDA drug label explicitly states: "In view of the lack of experience with the use of this drug in pediatric patients, it is not recommended at the present time for patients under 12 years of age." 1 This is a clear regulatory limitation that must be respected in clinical practice.
Evidence-Based Reality: Amitriptyline's Limited Efficacy
Despite widespread historical use, the highest quality evidence demonstrates amitriptyline's disappointing performance:
- The 2017 CHAMP trial (the definitive pediatric migraine prevention study) found no significant difference between amitriptyline, topiramate, and placebo in children ages 8-17 years 2
- 52% response rate with amitriptyline vs. 61% with placebo (P=0.26) 2
- The trial was stopped early for futility 2
Current Guideline Recommendations
The 2020 AAN/American Headache Society guidelines acknowledge this evidence gap and recommend: "Discuss with patients/families whether to use a preventive medication, since placebo was as effective as the studied medication in many trials." 3
The guidelines suggest amitriptyline combined with cognitive behavioral therapy may be considered (Level B evidence), but notably, amitriptyline alone showed no superiority over placebo 3
Dosing (If Used Despite Limited Evidence)
When amitriptyline is used off-label in children ≥12 years:
- Standard dose: 1 mg/kg/day 2, 4
- Titrate slowly over 8 weeks to target dose 2
- Given once daily (typically at bedtime due to sedation)
- An older study from 2000 reported 84% subjective improvement with this dosing, but this predated the placebo-controlled CHAMP trial 4
Critical Safety Considerations
Amitriptyline carries significant risks in pediatric populations:
- Mood alterations and suicidality: Three patients had serious adverse events of altered mood in the CHAMP trial, and one suicide attempt occurred 2
- Common adverse effects: Fatigue (30% vs. 14% placebo), dry mouth (25% vs. 12% placebo) 2
- Cardiac risks: Can cause arrhythmias, sinus tachycardia, and conduction delays 1
- Anticholinergic effects: Particularly problematic in children
Clinical Algorithm
For children with frequent/disabling migraine:
- Age <12 years: Do NOT use amitriptyline per FDA labeling 1
- Age ≥12 years:
- First, have a detailed discussion with family about the high placebo response rate (61%) and lack of proven benefit over placebo 2
- Consider lifestyle modifications, trigger avoidance, and cognitive behavioral therapy first 3
- If pharmacologic prevention is still desired, consider topiramate or propranolol as alternatives (though these also showed no superiority to placebo in CHAMP) 2
- If amitriptyline is chosen despite limited evidence: Start low, titrate to 1 mg/kg/day over 8 weeks, monitor closely for mood changes 2
Common Pitfall
The major pitfall is assuming amitriptyline is effective based on older, uncontrolled studies or adult data. The 2017 CHAMP trial definitively showed no benefit over placebo in the pediatric population 2. Clinicians must counsel families about this reality rather than perpetuating outdated practice patterns.